Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Eledon Pharmaceuticals Inc ELDN

Healthcare Biotechnology
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular... see more

Recent & Breaking News (NDAQ:ELDN)

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

GlobeNewswire March 28, 2024

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

GlobeNewswire March 25, 2024

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

GlobeNewswire March 21, 2024

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 13, 2024

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

GlobeNewswire January 4, 2024

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 4, 2023

Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

GlobeNewswire November 29, 2023

Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

GlobeNewswire November 9, 2023

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

GlobeNewswire November 8, 2023

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

GlobeNewswire November 2, 2023

Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

GlobeNewswire October 23, 2023

Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting

GlobeNewswire October 13, 2023

Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors

GlobeNewswire October 2, 2023

Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human

GlobeNewswire September 25, 2023

Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 20, 2023

Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors

GlobeNewswire September 11, 2023

Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates

GlobeNewswire September 6, 2023

Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation

GlobeNewswire September 5, 2023

Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation

GlobeNewswire August 16, 2023

Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results

GlobeNewswire August 10, 2023